Ozempic Reimbursement Expands to Include More Adults with Type 2 Diabetes and Obesity
Table of Contents
More adults living with type 2 diabetes and qualifying obesity criteria will now have access to reimbursed Ozempic treatment,thanks to a recent shift in coverage policies.The injectable medication, containing the active ingredient semaglutide, is seeing expanded access, but key stipulations remain regarding eligibility and usage.
Why did this change happen? The coverage policy was updated following an evaluation by Infarmed, Portugal’s national authority for health, to broaden access to Ozempic for individuals with type 2 diabetes and obesity, particularly those at risk of cardiovascular disease. The goal is to improve treatment options for a larger patient population.
Who Qualifies for ozempic Reimbursement?
Previously, reimbursement for Ozempic was limited to individuals with type 2 diabetes and a body mass index (BMI) of 35 or higher, classifying them as having class 2 obesity. The updated policy, following a recent evaluation by Infarmed, broadens access to include those with a BMI of 30 or greater (class 1 obesity) or those at elevated risk of cardiovascular disease, irrespective of their BMI.
“This change significantly expands the potential patient pool eligible for Ozempic coverage,” a senior official stated. However, it’s crucial to understand that reimbursement remains exclusively for the treatment of insufficiently controlled type 2 diabetes.
Who benefits from this change? Adults with type 2 diabetes who have a BMI of 30 or higher, or those with type 2 diabetes and a high risk of cardiovascular disease, are now eligible for reimbursement. This expands the previous eligibility criteria of a BMI of 35 or higher.
What Has Changed – and What Hasn’t?
The core indication for Ozempic remains unchanged: it is indeed intended as an adjunct to diet and exercise when first-line treatments, such as metformin, prove ineffective, are contraindicated, or are poorly tolerated. The new policy doesn’t open the door to Ozempic coverage for weight loss alone.
Hear’s a breakdown of the key changes:
- BMI Threshold: Lowered from 35 to 30 for individuals with type 2 diabetes.
- Cardiovascular Risk: Inclusion of patients with a high risk of cardiovascular disease, irrespective of BMI.
- Core Indication: Remains limited to insufficiently controlled type 2 diabetes.
- Reimbursement Level: Continues at 90%.
What specifically changed in the reimbursement policy? The BMI threshold for eligibility was lowered from 35 to 30, and patients with a high risk of cardiovascular disease are now included regardless of their BMI. The reimbursement level remains at 90%. Ozempic is not covered for weight loss alone.
Accessing Ozempic reimbursement requires adherence to a specific process. The exceptional reimbursement regime remains in place, meaning the relevant ordinance must be explicitly mentioned on the prescription. Furthermore, the medication must be prescribed by physicians specializing in endocrinology and nutrition, internal medicine, pediatrics, or general and family medicine.
How does a patient access the reimbursement? Patients must receive a prescription from a qualified physician (endocrinology,nutrition,internal medicine,pediatrics,or general/family medicine) that explicitly mentions the relevant ordinance for exceptional reimbursement.
